Wegovy Tablets
Wegovy tablets contain semaglutide, the same active ingredient as the Wegovy injection, and work by mimicking a natural hormone that signals to your brain when you're full, helping to reduce appetite and how much you eat.
Up to 20.7% weight loss
GLP-1
Semaglutide
Prices from
£TBC
Get started
Up to 17%* body weight reduction with Wegovy
Sourced directly from manufacturer Novo Nordisk
UK-based clinical expertise and monthly check-ins
No hidden fees (pay-as-you-go)
Learn about Wegovy before you buy
About Wegovy tablets
The key difference from the injection is simply that the tablet is taken once-daily instead of a once-weekly injection. The tablet of course means no needles and there is also no refrigeration required.
Wegovy tablets were approved by the FDA in December 2025 and became available in the US from January 2026. UK approval is expected later in 2026, subject to review by the MHRA. Phlo Clinic will offer them as soon as they become available.
What are Wegovy tablets
Tablet-based weight loss treatments
Contain a GLP-1 receptor agonist (the same active ingredient as Wegovy)
Taken once daily orally, rather than once weekly by injection
Clinically tested with results comparable to injectable options
Why are people interested?
A non-injectable alternative for those who prefer not to use a pen
Easier to fit into everyday life for some people
No refrigeration or injection equipment required
The same clinically-led approach, in a simpler format
How effective is Wegovy for weight loss?
Are Wegovy tablets effective?
In the OASIS 4 phase 3 trial (a 64-week study of 307 adults with obesity or overweight) people taking Wegovy tablets lost an average of 13.6% of their body weight, compared to 2.2% on placebo. Results were comparable to those seen with the Wegovy injection in earlier trials, suggesting the tablet delivers similar clinical benefit despite the different delivery method.
13.6%
average body weight lost over 64 weeks
60%
of patients lost at least 10% of body weight
28%
of patients lost at least 20% of body weight
Weight loss calculator
kgs
lbs
Select your current weight:
kgs
Weight you could lose:
144
kgs
*This calculator is only an example for illustrative purposes and the results are not guaranteed. Every weight loss experience is unique. ASIS 4 phase 3 trial (a 64-week study of 307 adults with obesity or overweight) people taking Wegovy tablets lost an average of 13.6% of their body weight, compared to 2.2% on placebo.
Compare Wegovy tablets and injections
Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:
Format
Availability
Clinically proven
Weight loss (avg)
Ongoing support
Best for
Wegovy
GLP-1 tablets
Once daily tablet
Coming soon
Yes
Up to ~17%
Yes – always included with Morrisons Clinic
People who prefer not to inject
Wegovy
FlexTouch Pen
Once-weekly injection (pen)
Available now
Yes
Up to ~20%
Yes – always included with Morrisons Clinic
People who want treatment now
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Both treatments are not yet available in the UK. Availability is subject to regulatory approval. Both expected in 2026.
Wegovy tablet dosage
Wegovy tablets follow a gradual four-step titration schedule, starting at a low dose of 1.5mg daily and increasing at a minimum every four weeks, giving your body time to adjust and helping to minimise digestive side effects like nausea. The full maintenance dose of 25mg once daily is typically reached by week 16 of treatment if you respond well, and is taken long-term to maintain weight loss results.
*Get your first 2.5mg KwikPen at the starting price of £129, with subsequent 2.5mg orders increasing to £159 thereafter. Prices checked and accurate as at 14 June 2024.
Dosage schedule
The tablet is taken once daily on an empty stomach, with a small amount of water, followed by a 30-minute wait before eating, drinking anything other than water, or taking other oral medicines. This fasting window is important for the medication to absorb properly.
1.5mg
Once daily
Days 1-30
4mg
Once daily
Days 31-60
9mg
Once daily
Days 61-90
25mg
Once daily
Days 91+
1.5mg
Once daily
Step 1
Weeks 1-4
4mg
Once daily
Step 2
Weeks 5-8
9mg
Once daily
Step 3
Weeks 9-12
25mg
Once daily
Step 4
Weeks 13+
What to expect
Step 1
Your body begins adjusting to semaglutide. Mild nausea is common during this phase and usually settles quickly.
Step 2
Appetite begins to reduce noticeably for most patients. Continue taking on an empty stomach each morning.
Step 3
Weight loss typically becomes more consistent at this stage. Side effects, if any, are usually milder than in earlier weeks.
Step 4
Full therapeutic dose for ongoing weight management. This is the dose used throughout the OASIS 4 clinical trial, in which patients lost an average of 13.6% of body weight.
The schedule above is based on the FDA-approved US prescribing information. Guidance will be confirmed by the MHRA on approval. Always follow the dosage instructions provided by your Phlo Clinic clinician and do not adjust your dose without speaking to a healthcare professional first.
How to take your wegovy tablet
1
Take first thing in the morning on an empty stomach, before eating or drinking anything other than water
2
Use a small amount of water, no more than around 120ml (4oz); do not take with other drinks
3
Wait 30 minutes before eating, drinking anything else, or taking other oral medicines; this allows the semaglutide to absorb properly
4
If you miss a dose, skip it and take your next tablet at the usual time the following day; do not take two doses to make up for a missed one
Source: Novo Nordisk. Wegovy (semaglutide) tablet US prescribing information, 2026.
Titration schedule based on FDA-approved labelling. UK dosing may vary subject to MHRA guidance.
Can I switch from Wegovy injections to Wegovy tablets?
If you're currently taking Wegovy 2.4mg injections and want to switch to the tablet, you may be able to start at the full 25mg maintenance dose, skipping the titration steps entirely.
This would typically begin one week after your last injection, however is subject to a clinical review. One of our prescribers will assess your suitability as part of a switching consultation.
How it works
Get started in 3 easy steps
Choosing Morrisons Clinic means you’re in control of your healthcare. No more dreaded busy tone or long waiting lists – we’ve got you covered.
1
Complete switching consultation
One of our prescribing pharmacists will review your treatment history, current dose, and health profile to confirm you're a suitable candidate to switch.
2
Receive your prescription
If approved, your clinician will prescribe Wegovy tablets at the appropriate starting dose for a switch. Please note, this may differ from your current injection dose.
3
Begin your tablet treatment
We'll guide you through how to take the tablet, how to manage side effects, dose escalation schedule, and provide monthly check-ins as well as support via our patient care team, 7 days a week.
1
Complete switching consultation
One of our prescribing pharmacists will review your treatment history, current dose, and health profile to confirm you're a suitable candidate to switch.
2
Receive your prescription
If approved, your clinician will prescribe Wegovy tablets at the appropriate starting dose for a switch. Please note, this may differ from your current injection dose.
3
Begin your tablet treatment
Once approved and dispensed, we’ll securely deliver your treatment using our free Royal Mail Tracked 24 option.
The tablet is not simply a like-for-like swap: the dosing is different (25mg oral vs 2.4mg injectable), the fasting requirements are new, and your clinician will want to ensure you're stable on your current dose before any change is made.
Are Wegovy tablets safe to take?
Wegovy tablets have a well-established safety profile, consistent with semaglutide in its injectable form, which has been used by millions of patients worldwide. In the OASIS 4 trial, serious adverse events were actually less common in the treatment group than in the placebo group (3.9% vs 8.8%), and fewer than 7% of patients stopped treatment due to side effects.
s with any prescription medicine, Wegovy tablets are not suitable for everyone. They should not be taken by people with a personal or family history of medullary thyroid cancer or MEN2, and are not currently approved for use during pregnancy. Our clinical team will assess your suitability before any prescription is issued.
Clinically tested - approved by the FDA following a phase 3 randomised controlled trial
Side effects are mostly mild - the most common are nausea and vomiting, typically during dose escalation, and settling down over time for most patients
Prescriber-led at Phlo Clinic - our clinicians will review your health history before prescribing and monitor you throughout treatment
Trusted experts, trusted outcomes
Start your weight loss journey with Morrisons Clinic
Wegovy tablet FAQs
Wegovy tablet side effects
Side effects of tablets vs injection
How do side effects compare to Wegovy injections
Weight loss help centre
Got weight loss questions?
Get weight loss answers.
Find out what you need to know about how our weight loss service works. From ordering to payments and everything in between - read the latest from our specialists.
Visit help centre
Weight loss
Wegovy tablets
Start your oral weight loss journey
Morrisons Clinic
Unit 1 Fifth Street
Trafford Park
Manchester
England
M17 1JX
Dennis Ouko
MRPharmSGPhC
Registration Number: 2205052
Phlo Technologies Ltd
